Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study.
Elisa Llurba, Fatima Crispi, Francesca Crovetto...
https://pubmed.ncbi.nlm.nih.gov/38458783/Actively Recruiting
Led by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Updated on 2025-02-19
9132
Participants Needed
21
Research Sites
N/A
Total Duration
Preeclampsia PE affects about 5% of pregnancies and remains a major cause of illness and death for mothers worldwide. Term PE, which occurs at or after 37 weeks, accounts for 70% of all PE cases and leads to significant health risks for mothers and babies. Researchers are studying whether a simple blood test screening using the sFlt1PlGF ratio at 35 to 37 weeks, followed by planned induction of labor IOL from 37 weeks in high-risk women, can reduce the occurrence of term PE without increasing cesarean deliveries or harming newborns. The study compares two groups of first-time pregnant women one group will have their sFlt1PlGF ratio results revealed to doctors and receive an offer of induction from 37 weeks if their risk is high above the 90th percentile, while the other group will have their results concealed and receive routine care. The screening test is a single-step blood test done between 35.0 and 36.6 weeks. Induction of labor is planned only for those with a high-risk test result in the revealed group. The other group will continue with standard pregnancy follow-up and spontaneous delivery. Participants will be monitored for the development of term PE and other maternal and newborn health outcomes for up to 6 months after delivery. Researchers will assess rates of term PE within 4 weeks, cesarean section rates, maternal and neonatal hospital stays, maternal complications, perinatal complications, maternal experience, and cardiovascular risk post-delivery. The study involves regular follow-up visits and data collection to evaluate the effectiveness and safety of the screening and intervention strategy.
CONDITIONS
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
E
Elisa Llurba, MD; PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead Sponsor
Fundacion Clinic per a la Recerca Biomédica
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo a single blood test to measure the sFlt1/PlGF ratio at 35 to 36.6 weeks of gestation to assess risk of developing term preeclampsia.
1 visit (in-person)
Duration - Up to 2 weeks or until delivery
Participants identified as high risk may be offered induction of labor starting at 37 weeks to prevent term preeclampsia. Others will continue with routine pregnancy care and spontaneous delivery.
1 to 2 visits depending on induction scheduling
Duration - Up to 18 weeks post-delivery
Participants are monitored for maternal and neonatal outcomes after delivery, including maternal morbidity, hospital stay, and perinatal complications.
Approximately 3 to 4 visits post-delivery
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Elisa Llurba, Fatima Crispi, Francesca Crovetto...
https://pubmed.ncbi.nlm.nih.gov/38458783/Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead Sponsor
Fundacion Clinic per a la Recerca Biomédica
Collaborating Sponsor